Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-7085 in Moderate to Severe Active Ulcerative Colitis
NCT07760831Phase 1Not yet recruiting
- Sponsor
- Hengrui
- Start
- Aug 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial in ulcerative colitis (UC) comparing Active treatment of HRS-7085 with Placebo (2 arms). Primary endpoint: Adverse Events at Week 12. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
HRS-7085
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07760831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07760831.